Pulmonary Arterial Hypertension Market to Generate Sales of Approximately $4.75 Billion by the End of 2024

Pune, April 26, 2016 (Newswire.com) - This report on the global pulmonary arterial hypertension (PAH) market offers an insightful and in-depth assessment of the current and future market potential of PAH drugs.

The report,” Pulmonary arterial hypertension market”  provides analysis of the Pulmonary Arterial Hypertension (PAH) therapeutics space across the 7MM, including annualized market data from 2014 and forecast to 2024. It discusses market characterization, unmet needs, clinical trial mapping and implications for the PAH treatment arena.

Browse Detailed Toc, Tables, Figures, Charts and Companies Mentioned in Pulmonary Arterial Hypertension - Opportunity Analysis and Forecast Report at - http://www.absolutereports.com/opportunityanalyzer-pulmonary-arterial-hypertension-opportunity-analysis-and-forecast-to-2024-10120403

The latest report on Pulmonary arterial hypertension market states that the increase in PAH treatment sales, which will occur across the seven major markets of the US, France, Germany, Italy, Spain, the UK, and Japan, will be driven by new drug launches, the increased use of double and triple combination therapies, and patient assistance programs by manufacturers.

Ask for Discount on Pulmonary Arterial Hypertension - Opportunity Analysis and Forecast Report at – http://www.absolutereports.com/enquiry/request-discount/10120403

The study on the global PAH market also suggests a list of recommendations for new companies aspiring to enter the market and existing companies willing to accentuate revenue shares. The report concludes with the profiles of major players in the global PAH market such as Actelion Pharmaceuticals, Ltd., Bayer HealthCare, Gilead Sciences, Inc., GlaxoSmithKline plc, Novartis International AG, Pfizer, Inc., and United Therapeutics Corporation. Each company profile in the report provides information under the heads: company overview, financial overview, product portfolio, business strategies, and recent developments.

Request sample PDF of this report at - http://www.absolutereports.com/enquiry/request-sample/10120403

Key Findings of this Report:

- The major drivers for growth across the 7MM in the PAH market during the forecast period will be the launch of the first-in-class prostacyclin receptor agonist, Uptravi marketed by Actelion and the increased use of combination therapy.

- Low disease awareness, declining population in the 5EU and Japan, high cost of drugs and patent expirations of branded drugs are the major barriers for growth in the PAH market during the forecast period.

About Absolute Report: Absolute Reports is an upscale platform to help key personnel in the business world in strategizing and taking visionary decisions based on facts and figures derived from in depth market research. We are one of the top report resellers in the market, dedicated towards bringing you an ingenious concoction of data parameters.

Contact–
Mr. Ameya Pingaley
Absolute Reports
+1-408 520 9750
Email – [email protected]

Website: www.absolutereports.com

Source: Absolute Reports